Proteomic Alterations in Multiple Myeloma: A Comprehensive Study Using Bone Marrow Interstitial Fluid and Serum Samples

Chanukuppa, Venkatesh; Taware, Ravindra; Taunk, Khushman; Chatterjee, Tushar; Sharma, Sanjeevan; Somasundaram, Venkatesan; Rashid, Faraz; Malakar, Dipankar; Santra, Manas Kumar; Rapole, Srikanth

doi:10.3389/fonc.2020.566804

Cited by 19 publications

(14 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Jinfang Xu et al found the forced expression of Kininogen-1 represses the glioma cells proliferation and promotes apoptosis 41 . Proteomic data showed the Kininogen 1 is closely related to the development of MM 42 . GPCR and RGS signaling pathways play key roles in maintaining the cell functions and metabolisms [43][44][45][46] .…”

Section: Discussionmentioning

confidence: 99%

Identification of candidate therapeutics and signaling pathways for multiple myeloma

2021

Preprint

View full text Add to dashboard Cite

Multiple myeloma (MM), a plasma cell malignancy, is related to critical morbidity due to end-organ destruction. A number of factors affect the MM cell proliferation and functions. Though MM is not curable, novel targets and inhibitors have shown great effects on MM patients. Here, we aim to identify significant genes and signaling pathways of MM with SI2 treatment using a bioinformatics method. The GSE156871 dataset was originally produced by using the high-throughput BGISEQ-500. The KEGG and GO results suggested that biological pathways such as “the complement and coagulation cascades” and “the transcription activator activity” are mostly affected in the SI2 treatment of MM cells. Moreover, we identified several genes including SRC, KNG1, and PI3KCG were involved in the treatment of MM cells. Therefore, our study provides further insights into the treatment of MM.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of candidate therapeutics and signaling pathways for multiple myeloma

2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Serum concentrations of S100A8 and LRG1 were measured using human S100A8 and LRG1 ELISA assay kits (Uscn, China), respectively. ELISAs were performed as previously described ( 12 ) according to manufacturer’s instructions. The absorbance values of the standards and samples were determined by spectrophotometry at 450 nm using a microplate reader.…”

Section: Methodsmentioning

confidence: 99%

iTRAQ-Based Proteomic Analysis Reveals Potential Serum Biomarkers for Pediatric Non-Hodgkin’s Lymphoma

Yang

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Non-Hodgkin’s lymphoma (NHL) is the third most common malignant tumor among children. However, at initial NHL diagnosis, most cases are at an advanced stage because of nonspecific clinical manifestations and currently limited diagnostic methods. This study aimed to screen and verify potential serum biomarkers of pediatric NHL using isobaric tags for relative and absolute quantification (iTRAQ)-based proteomic analysis. Serum protein expression profiles from children with B-NHL (n=20) and T-NHL (n=20) and healthy controls (n=20) were detected by utilizing iTRAQ in combination with two-dimensional liquid chromatography-tandem mass spectrometry (2D LC–MS/MS) and analyzed by applying Ingenuity Pathway Analysis (IPA). The candidate biomarkers S100A8 and LRG1 were further validated by using enzyme-linked immunosorbent assays (ELISAs). Receiver operating characteristic (ROC) analysis based on ELISA data was used to evaluate diagnostic efficacy. In total, 534 proteins were identified twice using iTRAQ combined with 2D LC–MS/MS. Further analysis identified 79 and 73 differentially expressed proteins in B-NHL and T-NHL serum, respectively, compared with control serum according to our defined criteria; 34 proteins were overexpressed and 45 proteins underexpressed in B-NHL, whereas 45 proteins were overexpressed and 28 proteins underexpressed in T-NHL (p < 0.05). IPA demonstrated a variety of signaling pathways, including acute phase response signaling and liver X receptor/retinoid X receptor (LXR/RXR) activation, to be strongly associated with pediatric NHL. S100A8 and LRG1 were elevated in NHL patients compared to normal controls according to ELISA (p < 0.05), which was consistent with iTRAQ results. The areas under the ROC curves of S100A8, LRG1, and the combination of S100A8 and LRG1 were 0.873, 0.898 and 0.970, respectively. Our findings indicate that analysis of the serum proteome using iTRAQ combined with 2D LC–MS/MS is a feasible approach for biomarker discovery. Serum S100A8 and LRG1 are promising candidate biomarkers for pediatric NHL, and these differential proteins illustrate a novel pathogenesis and may be clinically helpful for NHL diagnosis in the future.

show abstract

“…Deregulation of protein expression was reported in MM patients compared to non-malignant samples, demonstrating their diagnostic and/or prognostic potentials. Several studies showed a differential expression of various proteins such as haptoglobin, kininogen 1, transferrin, serum amyloid A protein, plasma kallikrein, integrin alpha-11, apolipoprotein A-I, sulfhydryl oxidase 1 and isoform-1 of multimerin-1 in the sera of MM patients [ 128 , 129 , 130 ].…”

Section: Novel Biomarkers For Diagnosis and Prognosis Of MMmentioning

confidence: 99%

Next-Generation Biomarkers in Multiple Myeloma: Understanding the Molecular Basis for Potential Use in Diagnosis and Prognosis

Soliman

Das

Teoh

2021

IJMS

View full text Add to dashboard Cite

Multiple myeloma (MM) is considered to be the second most common blood malignancy and it is characterized by abnormal proliferation and an accumulation of malignant plasma cells in the bone marrow. Although the currently utilized markers in the diagnosis and assessment of MM are showing promising results, the incidence and mortality rate of the disease are still high. Therefore, exploring and developing better diagnostic or prognostic biomarkers have drawn global interest. In the present review, we highlight some of the recently reported and investigated novel biomarkers that have great potentials as diagnostic and/or prognostic tools in MM. These biomarkers include angiogenic markers, miRNAs as well as proteomic and immunological biomarkers. Moreover, we present some of the advanced methodologies that could be utilized in the early and competent diagnosis of MM. The present review also focuses on understanding the molecular concepts and pathways involved in these biomarkers in order to validate and efficiently utilize them. The present review may also help in identifying areas of improvement for better diagnosis and superior outcomes of MM.

show abstract

Proteomic Alterations in Multiple Myeloma: A Comprehensive Study Using Bone Marrow Interstitial Fluid and Serum Samples

Cited by 19 publications

References 82 publications

Identification of candidate therapeutics and signaling pathways for multiple myeloma

Identification of candidate therapeutics and signaling pathways for multiple myeloma

iTRAQ-Based Proteomic Analysis Reveals Potential Serum Biomarkers for Pediatric Non-Hodgkin’s Lymphoma

Next-Generation Biomarkers in Multiple Myeloma: Understanding the Molecular Basis for Potential Use in Diagnosis and Prognosis

Contact Info

Product

Resources

About